OAB is a common and distressing chronic bladder condition presenting
with symptoms of urinary frequency, urgency, and urge incontinence.
Pharmacotherapy with antimuscarinic agents is one of the major treatment
options for OAB. Mirabegron in combination with antimuscarinic drugs is being
used for treatment-resistant OAB. Given that the two groups have different
modes of action, it is logical to think that combination therapy would have
advantages over monotherapy